Steens Jennifer, Klein Diana
Institute for Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Stem Cells Int. 2018 Aug 26;2018:6726185. doi: 10.1155/2018/6726185. eCollection 2018.
Mesenchymal stem cells (MSCs) are heterogeneous multipotent stem cells that are involved in the development of mesenchyme-derived evolving structures and organs during ontogeny. In the adult organism, reservoirs of MSCs can be found in almost all tissues where MSCs contribute to the maintenance of organ integrity. The use of these different MSCs for cell-based therapies has been extensively studied over the past years, which highlights the use of MSCs as a promising option for the treatment of various diseases including autoimmune and cardiovascular disorders. However, the proportion of MSCs contained in primary isolates of adult tissue biopsies is rather low and, thus, vigorous ex vivo expansion is needed especially for therapies that may require extensive and repetitive cell substitution. Therefore, more easily and accessible sources of MSCs are needed. This review summarizes the current knowledge of the different strategies to generate human MSCs as an alternative method for their applications in regenerative therapy.
间充质干细胞（MSCs）是异质性多能干细胞，在个体发育过程中参与间充质来源的不断演变的结构和器官的发育。在成年生物体中，几乎在所有组织中都能找到间充质干细胞库，间充质干细胞在这些组织中有助于维持器官的完整性。在过去几年中，人们对使用这些不同的间充质干细胞进行细胞治疗进行了广泛研究，这突出了间充质干细胞作为治疗包括自身免疫性疾病和心血管疾病在内的各种疾病的有前景选择的用途。然而，成人组织活检的原代分离物中间充质干细胞的比例相当低，因此，特别是对于可能需要大量和重复细胞替代的治疗，需要进行有力的体外扩增。因此，需要更容易获得的间充质干细胞来源。本综述总结了目前关于生成人源间充质干细胞的不同策略的知识，作为其在再生治疗中应用的替代方法。
